Comprehensive Medical & Scientific Disclaimer
Effective Date: September 22, 2026 • Governing Standards: FDA SaMD Wellness Exemption, EU MDR 2017/745, CDSCO India
MEDICAL EMERGENCY PROTOCOL — DIAL LOCAL EMERGENCY SERVICES IMMEDIATELY
IF YOU ARE CURRENTLY EXPERIENCING A MEDICAL EMERGENCY, SEVERE HYPOGLYCEMIA, ACUTE CHEST PAIN, SHORTNESS OF BREATH, SUDDEN VISION LOSS, LOSS OF CONSCIOUSNESS, OR SEVERE ABDOMINAL DISTRESS, DO NOT CONSULT THIS APPLICATION. CEASE APPLICATION USE IMMEDIATELY AND DIAL YOUR REGIONAL EMERGENCY DISPATCH NUMBER:
1. Not Medical Advice & No Clinical Relationship
The services, algorithms, nutritional sequencing guides, meal order calculations, circadian timers, and AI conversational assistants provided by Tovelu Health Technologies Private Limited ("Tovelu") are designed strictly for general health, wellness, and educational purposes.
Tovelu does not provide medical diagnosis, clinical prognosis, pharmaceutical prescription, or personalized medical therapies. Nothing contained within the Tovelu application, documentation, or marketing communications should be construed as:
- The practice of medicine, nursing, pharmacy, or any licensed clinical healthcare discipline.
- The establishment of a doctor-patient, dietitian-patient, or confidential therapeutic relationship.
- A recommendation to initiate, modify, pause, or terminate any prescription medication or clinical treatment plan.
2. Regulatory Non-Device Status (FDA, EU MDR, UK MHRA, CDSCO)
Tovelu is explicitly classified as Non-Device General Wellness Software and is NOT a regulated medical device under international health regulatory regimes:
United States (FDA Compliance)
Pursuant to Section 520(o)(1) of the 21st Century Cures Act and the U.S. Food and Drug Administration (FDA) Guidance for "Policy for Device Software Functions and Mobile Medical Applications" and "General Wellness: Policy for Low Risk Devices", Tovelu functions solely as an interactive lifestyle management and nutritional pacing tool and is exempt from FDA 510(k) premarket notification requirements.
European Union & UK (MDR 2017/745)
Tovelu does not possess an intended medical purpose as defined under Article 2(1) of Regulation (EU) 2017/745 (Medical Device Regulation - MDR) or the UK Medical Devices Regulations 2002. It is not intended to treat, cure, or diagnose acute pathology.
3. Critical Medication Warning (Insulin, Sulfonylureas & Hypoglycemia)
RAPID METABOLIC SHIFTS & PHARMACEUTICAL DOSAGE ADVISORY
Implementing Tovelu nutritional protocols — specifically Pre-Meal Fiber Ingestion, Protein Pacing, Carbohydrate Delay, and 10-Minute Postprandial Ambulation — can significantly blunt post-meal glucose absorption and rapidly enhance biological insulin sensitivity.
ATTENTION: PATIENTS PRESCRIBED GLUCOSE-LOWERING MEDICATIONS
If you take exogenous insulin, sulfonylureas (e.g., glimepiride, glipizide, glyburide), SGLT2 inhibitors, or GLP-1 receptor agonists, sudden dietary changes without clinical dosage adjustments may precipitate severe hypoglycemia (dangerously low blood sugar).
MANDATORY REQUIREMENT: You MUST notify your prescribing physician, endocrinologist, or diabetologist BEFORE implementing Tovelu meal sequencing protocols, and perform frequent blood glucose self-monitoring under their supervision.
4. Scientific Literature & Mathematical Modeling Grounding
Tovelu algorithmic sequencing models are grounded in peer-reviewed clinical metabolic research, including landmark investigations published in journals such as Diabetes Care, The American Journal of Clinical Nutrition, and Nutrients regarding food order (nutrient sequencing) and incretin secretion (GLP-1 and CCK kinetics).
Nutritional reference values are matched against public laboratory databases maintained by the United States Department of Agriculture (USDA FoodData Central) and the Indian Council of Medical Research - National Institute of Nutrition (ICMR-NIN Indian Food Composition Tables).
5. Biological Individuality & Variability of Results
Human physiological responses to nutrition and physical movement are subject to profound inter-individual heterogeneity governed by genetics, gut microbiome taxonomy, pancreatic beta-cell mass, sleep quality, psychological stress, and underlying chronic pathologies.
Statistical statements presented across our platform (e.g., "blunts postprandial glucose spike by up to 73%") describe maximal experimental reductions documented in controlled clinical trial cohorts consuming specific carbohydrate challenges preceded by dietary fiber and protein. Such statements do NOT guarantee an identical, predictable, or uniform physiological result for every individual.
6. Continuous Glucose Monitors (CGMs) & Biometric Wearables
Tovelu allows users to manually review or input glucose telemetry derived from commercial Continuous Glucose Monitors (CGMs) or smart wearables (e.g., Abbott FreeStyle Libre, Dexcom, Ultrahuman, Apple Watch, Oura).
- CGM interstitial fluid sensor measurements exhibit a natural 5- to 15-minute physiological lag relative to venous blood glucose.
- Tovelu is not affiliated with, endorsed by, or responsible for hardware sensor errors, pressure-induced sensor dropouts, calibration inaccuracies, or device failures.
- Never base critical insulin dosing decisions solely on retrospective software graphs without verifying symptoms against a fingerstick capillary blood glucose test.
7. Voluntary Assumption of Risk
By accessing and executing any protocol within the Tovelu platform, you knowingly, freely, and voluntarily assume all biological, physical, and financial risks associated with altering your nutritional timing, portion sizing, macronutrient distribution, sleep schedule, and physical exercise routines. You release Tovelu Health Technologies Private Limited and its directors from any and all claims related to adverse health events or metabolic complications.
8. Physician & Clinical Partner Inquiries
Corporate Entity: Tovelu Health Technologies Private Limited
Medical & Regulatory Communications: legal@tovelu.store
Clinical Research / Academic Inquiries: contact@tovelu.store